Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia

Not Applicable

Completed

• Conditions: Postoperative Pain
• Interventions: Drug: Lidocaine; Drug: Nalbuphine

• Registration Number: NCT02678585
• Lead Sponsor: Assiut University

Brief Summary

The effect of addition of nalbuphine to lidocaine in intravenous regional anesthesia

Detailed Description

Not available

Study Timeline

• Study Start: 2015-12
• Study First Submitted: 2016-02-04
• Study First Submitted QC: 2016-02-05
• Study First Posted: 2016-02-10
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-23
• Last Update Posted: 2018-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• adult patients
• American Society of Anesthesiologists (ASA) physical status I-II
• age between 20 and 50 years old
• scheduled for elective unilateral short hand surgery

Exclusion Criteria

• allergy to study medications
• body mass index > 35 kg/m2
• patients with sickle cell disease or Reynaud disease
• patient refusal

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Lidocaine	53 patients received intravenous regional lidocaine
Nalbuphine	Nalbuphine	53 patients received intravenous regional lidocaine plus Nalbuphine

Primary Outcome Measures

Name	Time	Method
Tourniquet and postoperative pain measured by visual analogue scale	4 hours

Secondary Outcome Measures

Name	Time	Method
Cortisol level	4 hours

Trial Locations

Locations (1)

Assiut university hospital; 🇪🇬 Assiut, Egypt